Candel Therapeutics Inc. (CADL)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
Candel Therapeutics NASDAQ: CADL is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief Scientific Officer Francesca Barone said at the Canaccord Genuity Growth Conference in Boston.
Candel Therapeutics: Getting Closer, And Building Out More Paths
Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission in prostate cancer with strong phase 3 data. CADL is well-capitalized, holding $194.8M in cash, providing runway into Q1 2028 and supporting pivotal trials in prostate and lung cancer. CAN-2409's phase 3 prostate cancer trial, conducted under Special Protocol Assessment, positions CADL for a potentially smoother regulatory review.
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential
Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncology company with a BLA-directed lead asset. CAN-2409 has achieved positive Phase III results in localized prostate cancer, with additional promising data in NSCLC and PDAC, supporting a 'pipeline in a product' thesis. CADL's valuation appears overly pessimistic given its regulatory catalysts, improved financial runway into Q1 2028, and multiple clinical-stage assets.
Candel Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 3 | $15 | $31.38 | $16.38 | 109.2% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 115,875 | $1.19M | $1.23M | $33,606.25 | 2.82% |
| NA Nizar Araji National Bank Of Canada /FI/ | 17 | $175.1 | $180.03 | $4.93 | 2.82% |
| BG Bart Gancher Intech Investment Management LLC | 12,601 | $74,980.75 | $133,444.59 | $58,463.84 | 77.97% |
 Point72 Asset Management LP Point72 Asset Management LP | 129,183 | $751,645.61 | $1.51M | $762,379.15 | 101.43% |
Candel Therapeutics Inc. (CADL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Candel Therapeutics Inc. ever had a stock split?
Candel Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Paul-Peter Tak CEO | NASDAQ (NMS) Exchange | 137404109 CUSIP |
| US Country | 55 Employees | - Last Dividend | - Last Split | 27 Jul 2021 IPO Date |
Overview
Candel Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company rooted in the discovery and development of novel immunotherapies aimed at treating cancer patients. With a focus on leveraging innovative technologies and scientific advances, Candel Therapeutics is committed to achieving breakthroughs in cancer treatment. Since its inception in 2003 under the name Advantagene, Inc., the company has undergone a significant evolution, culminating in a name change to Candel Therapeutics, Inc. in November 2020. Headquartered in Needham, Massachusetts, the organization continues to push the boundaries of cancer therapy with its diverse pipeline of drug candidates and proprietary discovery platforms.
Products and Services
- CAN-2409
- CAN-3110
- enLIGHTEN Discovery Platform
